Sermorelin

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Active malignancy: GH stimulation may promote tumor growth.
• History of malignancy: exercise caution; assess risk-benefit before initiating.
• Active acromegaly or conditions involving GH excess.
• Concurrent use with CJC-1295 No DAC, CJC-1295 DAC, or tesamorelin: direct GHRH receptor redundancy; do not stack two GHRH analogs.
• Concurrent use with HGH 191aa: exogenous GH bypasses the pituitary that sermorelin depends on; sermorelin stimulates a pituitary already suppressed by exogenous GH.
• Disruption of the hypothalamic-pituitary axis: pituitary adenoma, cranial radiation, pituitary surgery, or hypopituitarism.
• Concomitant high-dose glucocorticoid therapy: suppresses pituitary GH response.
• Uncontrolled diabetes mellitus or significant insulin resistance: GH elevation worsens glycemic control; monitor fasting glucose.
• Diabetic ketoacidosis.
• Pregnancy: safety not established.
• Breastfeeding: safety not established.
• Known hypersensitivity to sermorelin acetate or any excipients.
• Pediatric use in subjects with closed growth plates.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Injection site flushing and erythema: the most commonly reported adverse effect; localized redness, warmth, and itching at the injection site within minutes of administration.
• Mild water retention: GH-mediated sodium and fluid retention; the most conservative profile of all GHRH analogs in this database.
• Headache: vasodilation from GH pulse; typically mild and transient.
• Transient facial flushing: immediate post-injection vasodilation.
• Mild lethargy or fatigue: associated with the GH pulse.
• Dizziness: transient; post-injection.
• Nausea: rare at standard doses.
• Mild joint stiffness: GH-related periarticular fluid; less pronounced than CJC-1295 DAC.
• Tingling or numbness: mild paresthesia; less common than with longer-acting GHRH analogs.
• Vivid dreams: GH elevation during nocturnal sleep.
• Mild transient blood sugar changes: less clinically significant than with tesamorelin or HGH 191aa.
• Antibody formation: anti-sermorelin antibodies may develop with extended cycles; may reduce efficacy; clinically significant binding capacity is rare.
• Pituitary downregulation: lower risk than longer-acting GHRH analogs; 4-week washout is adequate for receptor recovery.
• Injection site pain: mild discomfort at subcutaneous administration site.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• PubMed search: Sermorelin